GO:0141069 receptor ligand inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0141069 receptor ligand inhibitor activity describes a molecular function in which a protein binds to and decreases the activity of the ligand of a signaling receptor.
• This function acts upstream of receptor activation and can be engineered by enforced recruitment of phosphatases to immune receptors.
• Ligand-receptor interactions are highly sensitive to subtle structural changes, which can dramatically alter transcriptional outcomes.
• Multivalent ligand architecture can influence receptor-ligand binding mechanisms and downstream signaling.
• Dysregulation of ligand-receptor systems, such as EGF/HER, is implicated in cancer and is a target for therapeutic intervention.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable functional dissection of receptor ligand inhibitor activity in disease contexts [2, 6].
Description
GO:0141069 receptor ligand inhibitor activity is a molecular function defined as binding to and decreasing the activity of the ligand of a signaling receptor. This term captures a regulatory mechanism that operates at the level of ligand availability or ligand function, thereby modulating receptor activation and downstream signaling. Unlike receptor antagonists that act directly on the receptor, receptor ligand inhibitors act on the ligand itself, providing a distinct layer of control over intercellular communication [1, 5]. Understanding this function is critical because ligand-receptor systems govern diverse processes including immune responses, development, and cancer progression [1, 7]. For researchers, GO:0141069 provides a precise annotation for proteins that dampen signaling by targeting ligands, enabling systematic study of their roles in health and disease [1, 3].
receptor ligand inhibitor activity At A Glance
| GO ID | GO:0141069 |
|---|---|
| GO term | receptor ligand inhibitor activity |
| Ontology | molecular_function |
| Synonym | signaling receptor ligand inhibitor activity |
| Definition | Binds to and decreases the activity of the ligand of a signaling receptor. |
| Major function | Negative regulation of receptor signaling by targeting the ligand. |
| Biological context | Immune regulation, cancer, development, and cell-cell communication. |
| Research relevance | Target for therapeutic modulation of ligand-receptor systems. |
What Is GO:0141069?
In simple terms, receptor ligand inhibitor activity means a protein grabs onto a signaling molecule (the ligand) and reduces its ability to activate its receptor. According to the QuickGO definition, this molecular function is defined as binding to and decreasing the activity of the ligand of a signaling receptor. It is distinct from receptor antagonist activity because the inhibitor targets the ligand rather than the receptor itself. This function can be mediated by direct sequestration, enzymatic modification, or enforced recruitment of inhibitory factors that modify the ligand or its availability.
Why Is receptor ligand inhibitor activity Important in Cell Biology?
Receptor ligand inhibitor activity is important because it provides a mechanism to fine-tune signaling without directly blocking the receptor. This is particularly relevant in immune signaling, where enforced recruitment of phosphatases to immune receptors can inhibit downstream activation. In cancer, ligand-receptor systems such as EGF/HER are frequently dysregulated, and targeting the ligand or its interaction with the receptor can alter transcriptional outcomes and tumor growth [3, 7]. Moreover, subtle changes in ligand-receptor interactions can dramatically alter transcriptional outcomes, highlighting the sensitivity of these systems to modulation. Understanding GO:0141069 therefore informs both basic signaling biology and therapeutic strategies.
• Provides a layer of negative regulation upstream of receptor activation.
• Can be engineered using enforced phosphatase recruitment to immune receptors.
• Influences transcriptional outcomes through subtle changes in ligand-receptor interactions.
• Relevant to cancer biology, including EGF/HER and KRAS-mutant pancreatic cancer [7, 8].
• Multivalent ligand architecture can modulate receptor-ligand binding mechanisms.
• Targeting nuclear receptors with degraders can impact ligand-dependent signaling.
• Plays a role in immune receptor inhibition.
• Can be studied using CRISPR knockout, point mutation, knock-in, and overexpression models [2, 6].
• Relevant to platelet integrin αIIbβ3 function and thrombosis.
• Informs development of therapeutics that target ligand-receptor systems.
What Happens During receptor ligand inhibitor activity?
Ligand recognition and binding
In simple terms: The inhibitor protein finds and attaches to the signaling ligand.
The first step in receptor ligand inhibitor activity is the specific binding of the inhibitor to its target ligand. This interaction can occur in the extracellular space or within intracellular compartments, depending on the ligand and inhibitor. For example, enforced recruitment of phosphatases to immune receptors can inhibit signaling by dephosphorylating key components, effectively reducing ligand activity. The binding event is governed by affinity and avidity, which can be influenced by multivalent ligand architecture.
Decrease of ligand activity
In simple terms: Once bound, the inhibitor reduces the ligand's ability to activate its receptor.
After binding, the inhibitor decreases the ligand's activity through various mechanisms, such as steric hindrance, conformational change, or enzymatic modification. This leads to reduced receptor activation and downstream signaling. Subtle changes in ligand-receptor interactions can dramatically alter transcriptional outcomes, underscoring the importance of this step. In immune cells, this can prevent excessive activation and maintain homeostasis.
Downstream signaling modulation
In simple terms: The reduced ligand activity changes what happens inside the cell.
The decrease in ligand activity translates into altered intracellular signaling. For instance, inhibition of EGF/HER ligand-receptor system can affect cancer cell proliferation and survival. In pancreatic cancer, CAF-derived PAI-1 can serve as an EGFR ligand, and its inhibition may affect KRAS-mutant tumor growth. These downstream effects are often context-dependent and can be studied using transcriptional profiling.
Feedback and regulation
In simple terms: The cell can adjust the inhibitor's activity to fine-tune signaling.
Receptor ligand inhibitor activity is subject to regulation by feedback loops and post-translational modifications. For example, ubiquitin-mediated processes can act as a brake on immune signaling, as seen with OsCERK1-triggered immunity in rice. Targeting nuclear receptors with PROTAC degraders can also modulate ligand-dependent signaling pathways. These regulatory mechanisms ensure that ligand inhibition is reversible and context-appropriate.
Key Genes Involved in GO:0141069 receptor ligand inhibitor activity
The following genes and proteins are involved in or regulated by receptor ligand inhibitor activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTPN6 | Phosphatase recruited to immune receptors to inhibit signaling | Engineered inhibition of immune receptor signaling |
| PTPN11 | Phosphatase involved in receptor signaling modulation | Potential target for enforced inhibition |
| EGFR | Receptor tyrosine kinase activated by ligands | Target in cancer, ligand inhibition studies |
| ERBB2 | HER2 receptor, ligand-receptor system component | Cancer therapy target |
| PAI-1 | Serpin that can act as an EGFR ligand | KRAS-mutant pancreatic cancer |
| NR1I2 | Pregnane X receptor, nuclear receptor | Modulators alter transcriptional outcomes |
| ITGA2B | Integrin alpha-IIb, part of αIIbβ3 | Platelet function and thrombosis |
| ITGB3 | Integrin beta-3, part of αIIbβ3 | Platelet function and thrombosis |
| OSCERK1 | Rice immune receptor kinase | Ubiquitin brake regulates immunity |
| PXR | Pregnane X receptor, nuclear receptor | Ligand-receptor interactions affect transcription |
| HER2 | Receptor tyrosine kinase | EGF/HER ligand-receptor system in cancer |
| HER3 | Receptor tyrosine kinase | EGF/HER ligand-receptor system in cancer |
| HER4 | Receptor tyrosine kinase | EGF/HER ligand-receptor system in cancer |
| EGF | Ligand for EGFR | Target for ligand inhibition |
| NR3C1 | Glucocorticoid receptor | Nuclear receptor targeted by degraders |
| ESR1 | Estrogen receptor | Nuclear receptor targeted by degraders |
| AR | Androgen receptor | Nuclear receptor targeted by degraders |
How Is receptor ligand inhibitor activity Regulated?
Receptor ligand inhibitor activity is regulated at multiple levels. Post-translational modifications, such as ubiquitination, can act as a brake on immune signaling, as shown for OsCERK1 in rice. Enforced recruitment of phosphatases to immune receptors can inhibit signaling, demonstrating that the localization and activity of inhibitory proteins are tightly controlled. Additionally, the expression and stability of ligands and their inhibitors can be influenced by transcriptional and degradative pathways, such as PROTAC-mediated degradation of nuclear receptors. These regulatory mechanisms ensure that ligand inhibition is dynamic and responsive to cellular needs.
receptor ligand inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Cancer (lung, breast, pancreatic) | Knockout or point mutation in cancer cell lines |
| PAI-1 | KRAS-mutant pancreatic cancer | Overexpression or knockout in pancreatic cancer models |
| PTPN6 | Immune disorders | Knock-in of phosphatase recruitment domains |
| ITGB3 | Thrombosis | Point mutation to alter ligand binding |
| NR1I2 | Drug metabolism and cancer | Knockout or overexpression for PXR modulator studies |
Cancer
Dysregulation of ligand-receptor systems is a hallmark of many cancers. The EGF/HER ligand-receptor system is frequently overactive in tumors, and targeting this system with ligand inhibitors or receptor antagonists is a therapeutic strategy. In KRAS-mutant pancreatic cancer, CAF-derived PAI-1 acts as an EGFR ligand and fuels tumor growth, suggesting that inhibiting this ligand could be beneficial. Subtle changes in ligand-receptor interactions can dramatically alter transcriptional outcomes, which may contribute to drug resistance and disease progression.
Immune disorders
Receptor ligand inhibitor activity is critical for preventing excessive immune activation. Enforced recruitment of phosphatases to immune receptors can inhibit signaling, which may be harnessed to treat autoimmune diseases or cytokine storms. In plants, a ubiquitin brake regulates OsCERK1-triggered immunity, illustrating the evolutionary conservation of ligand inhibition mechanisms.
Thrombosis and hemostasis
Integrin αIIbβ3 is a receptor on platelets that binds fibrinogen and other ligands. Inhibitors of this ligand-receptor interaction are used as antiplatelet agents. Understanding the structure and function of αIIbβ3 provides insights into how ligand inhibitors can modulate thrombosis.
From receptor ligand inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate inhibitor increase ligand activity? | Knockout cell line |
| Does a specific point mutation in the ligand affect inhibitor binding? | Point mutation knock-in |
| Can a tagged inhibitor be used to track ligand binding? | Tagged knock-in |
| Does overexpression of the inhibitor reduce receptor signaling? | Overexpression cell line |
| Can CRISPR library screening identify novel ligand inhibitors? | CRISPR library screening |
| Does enforced recruitment of a phosphatase inhibit immune receptor signaling? | Knock-in of recruitment domains |
How to Study the receptor ligand inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Identify inhibitors of ligand activity |
| Point mutation knock-in | Effect of specific amino acid changes | Dissect ligand-inhibitor interfaces |
| Tagged knock-in | Protein localization and interactions | Track inhibitor-ligand complexes |
| Overexpression | Gain of function | Suppress ligand-receptor signaling |
| CRISPR library screening | Phenotypic effects of gene perturbations | Discover novel ligand inhibitors |
| RNA-seq | Transcriptional changes | Assess downstream effects of ligand inhibition |
| Proteomics | Protein abundance and modifications | Identify post-translational regulation |
| Bioinformatics | Pathway and network analysis | Integrate multi-omics data |
CRISPR knockout and point mutation
CRISPR-Cas9 can be used to generate knockout cell lines for genes encoding putative receptor ligand inhibitors, allowing assessment of ligand activity and downstream signaling. Point mutations can be introduced to dissect specific residues required for ligand binding or inhibitory function.
Knock-in and tagged knock-in
Knock-in of epitope tags or fluorescent proteins enables visualization and biochemical isolation of inhibitor-ligand complexes. For example, enforced recruitment of phosphatases can be achieved by knocking in recruitment domains. Tagged knock-in models are valuable for studying real-time interactions.
Overexpression and CRISPR activation
Overexpression of candidate inhibitors can suppress ligand-receptor signaling, providing a gain-of-function approach. CRISPR activation (CRISPRa) can be used to upregulate endogenous inhibitor expression, offering a more physiological context.
Library screening and bioinformatics
Genome-wide CRISPR knockout or activation libraries can be screened to identify genes that modulate ligand-receptor signaling. Bioinformatics analysis of transcriptomic data can reveal pathways affected by ligand inhibition [6, 3].
How CRISPR Can Be Used to Study GO:0141069 receptor ligand inhibitor activity
Knockout
CRISPR knockout of a candidate receptor ligand inhibitor gene can lead to increased ligand activity and enhanced receptor signaling. This approach is useful for validating the inhibitory function of a gene in a physiological context.
Point Mutation
Introducing point mutations in the ligand or inhibitor can reveal critical residues for binding and inhibition. For example, subtle changes in ligand-receptor interactions can dramatically alter transcriptional outcomes, making point mutations powerful tools for functional dissection.
Knock-in
Knock-in of tags, reporter genes, or recruitment domains allows precise manipulation of inhibitor function. Enforced recruitment of phosphatases to immune receptors is an example of how knock-in can be used to inhibit signaling.
Overexpression
Overexpression of a receptor ligand inhibitor can suppress ligand-receptor signaling and is a straightforward gain-of-function approach. This can be achieved by stable transfection or CRISPR activation.
How EDITGENE Supports receptor ligand inhibitor activity Research
Researchers studying receptor ligand inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in ligand inhibition or is merely a bystander. This requires precise genetic models that can knockout, mutate, knock-in, or overexpress the gene of interest. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for receptor ligand inhibitor activity research.
Frequently Asked Questions About receptor ligand inhibitor activity
What is receptor ligand inhibitor activity?
It is a molecular function defined as binding to and decreasing the activity of the ligand of a signaling receptor, as described by GO:0141069.
What genes are involved in receptor ligand inhibitor activity?
Genes include PTPN6, PTPN11, EGFR, ERBB2, PAI-1, NR1I2, ITGA2B, ITGB3, and others listed in the key genes table [1, 3, 4, 7, 8].
How is receptor ligand inhibitor activity regulated?
It is regulated by post-translational modifications such as ubiquitination and phosphatase recruitment, as well as transcriptional and degradative pathways [1, 2, 6].
What diseases are associated with receptor ligand inhibitor activity?
Cancer, immune disorders, and thrombosis are associated with dysregulation of ligand-receptor systems [1, 4, 7, 8].
What research methods are used to study receptor ligand inhibitor activity?
CRISPR knockout, point mutation, knock-in, overexpression, library screening, RNA-seq, proteomics, and bioinformatics are commonly used [1, 3, 5, 6].
Can CRISPR be used to study receptor ligand inhibitor activity?
Yes, CRISPR-based models enable precise genetic manipulation to dissect the function of inhibitors in ligand-receptor signaling [1, 2, 6].
What is the GO ID for receptor ligand inhibitor activity?
The GO ID is GO:0141069.
What is the synonym for receptor ligand inhibitor activity?
The synonym is signaling receptor ligand inhibitor activity.
How does receptor ligand inhibitor activity affect transcription?
Subtle changes in ligand-receptor interactions can dramatically alter transcriptional outcomes, as shown for pregnane X receptor modulators.
What cell models are available for studying receptor ligand inhibitor activity?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, and CRISPR library screening services [1, 3, 5, 6].
Conclusion
GO:0141069 receptor ligand inhibitor activity represents a crucial molecular function that modulates signaling by targeting ligands. Its role in immune regulation, cancer, and thrombosis underscores its importance in both basic and translational research. By leveraging CRISPR-based models and bioinformatics, researchers can dissect the mechanisms and therapeutic potential of receptor ligand inhibitors. EDITGENE offers comprehensive services to support such studies, from knockout to library screening.
References
- 1. Fernandes RA et al.. 2020. Immune receptor inhibition through enforced phosphatase recruitment.. Nature 586(7831):779-784 PMID: 33087934
- 2. Wang G et al.. 2024. Release of a ubiquitin brake activates OsCERK1-triggered immunity in rice.. Nature 629(8014):1158-1164 PMID: 38750355
- 3. Huber AD et al.. 2026. Subtle changes in ligand-receptor interactions dramatically alter transcriptional outcomes of pregnane X receptor modulators.. Structure 34(1):87-99.e5 PMID: 41138720
- 4. Coller BS. 2015. αIIbβ3: structure and function.. J Thromb Haemost 13 Suppl 1(Suppl 1):S17-25 PMID: 26149019
- 5. Gestwicki JE et al.. 2002. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture.. J Am Chem Soc 124(50):14922-33 PMID: 12475334
- 6. Flanagan JJ et al.. 2019. Targeting Nuclear Receptors with PROTAC degraders.. Mol Cell Endocrinol 493:110452 PMID: 31125586
- 7. Esparís-Ogando A et al.. 2016. Targeting the EGF/HER Ligand-Receptor System in Cancer.. Curr Pharm Des 22(39):5887-5898 PMID: 27426127
- 8. Wang Y et al.. 2026. CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer.. Nat Commun 17(1) PMID: 42401551
